JASBIR BISLA: Open Payments
NPI 1528058500 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,211 in 191 payments from 18 companies in 2025. Trend: 2023 $2,581 · 2024 $3,088 · 2025 $3,211
Food & beverage: $3,211
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 53 | $780 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $408 |
| Lundbeck LLC | 17 | $308 |
| Otsuka America Pharmaceutical, Inc. | 13 | $254 |
| Neurocrine BioSciences, Inc. | 13 | $227 |
| Vanda Pharmaceuticals Inc. | 15 | $202 |
| Alkermes, Inc. | 10 | $194 |
| Janssen Pharmaceuticals, Inc | 8 | $166 |
| E.R. Squibb & Sons, L.L.C. | 8 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $139 |
Products named: VRAYLAR, REXULTI, CAPLYTA, INGREZZA, FANAPT, ARISTADA, COBENFY, TRINTELLIX.
Industry payments across AZ — which companies pay providers there.
